Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Tislelizumab and Chemotherapy in Locally Advanced OSCC/OPSCC
NCT06009861Phase 2Active, not recruiting
- Sponsor
- Peking University School and Hospital of Stomatology
- Start
- Jun 2023
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in oral squamous cell carcinoma (OSCC), oropharyngeal squamous cell carcinoma (OPSCC), sponsored by Peking University School and Hospital of Stomatology. Started Jun 2023; status: active, not recruiting.
02
Drugs
tislelizumab
03
Conditions
oral squamous cell carcinoma (OSCC)oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT06009861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06009861.